Presentations will summarize new preclinical data from brain-penetrant, pan-mutant B-Raf degrader program and recent clinical ...

The company provided clear evidence that it has plenty of resources to continue developing a potential blockbuster drug.

Earlier this year, Eshelman Innovation and the North Carolina Biotechnology Center hosted the 2024 N.C. Radiopharmaceuticals ...

J.P. Morgan has downgraded Dyne Therapeutics (DYN) to neutral from overweight, citing the stock’s outperformance this year.

Devoid of any marketed drug in its portfolio, investors will likely focus on SMMT's pipeline updates when it reports third-quarter results this month.

Bob Duggan is cashing in on a 689% rally in his Summit Therapeutics Inc. to buy one of the most expensive condos ever sold in Miami’s Brickell neighborhood.Duggan is buying a $33 million two-story ...

To say this has been a big year for Summit Therapeutics (NASDAQ: SMMT) would be a huge understatement. The stock has risen ...

The session will highlight latest developments in the company’s protein homeostasis program as BPGbio continues to advance ...

Bob Duggan, chairman and co-CEO of Summit Therapeutics Inc. SMMT, is capitalizing on a remarkable 689% stock surge to ...